Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda <i>et al</i>.

Immisch, Lena; Papafotiou, George; Popp, Oliver; Mertins, Philipp; Blankenstein, Thomas; Willimsky, Gerald

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.

Immisch, Lena; Papafotiou, George; Popp, Oliver; Mertins, Philipp; Blankenstein, Thomas; Willimsky, Gerald.

Afiliação

Immisch L; Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Papafotiou G; German Cancer Research Center, Heidelberg, Germany.
Popp O; German Cancer Consortium, partner site Berlin, Berlin, Germany.
Mertins P; Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Blankenstein T; German Cancer Research Center, Heidelberg, Germany.
Willimsky G; German Cancer Consortium, partner site Berlin, Berlin, Germany.

J Immunother Cancer ; 11(3)2023 03.

Article em En | MEDLINE | ID: mdl-36918223

Assuntos

Glioma; Antígeno HLA-A2; Humanos; Antígeno HLA-A2/genética; Histonas/genética; Glioma/genética; Glioma/terapia; Imunoterapia; Mutação

Palavras-chave

Antigens, Neoplasm; Immunotherapy; Immunotherapy, Adoptive

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno HLA-A2 / Glioma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google